Annexon (NASDAQ: ANNX) announced the appointment of Lloyd Clark, MD, as SVP, ophthalmology strategy and innovation.
Dr. Clark brings more than 25 years of experience in treating retinal diseases and advancing novel therapies, having served as a principal investigator in more than 70 clinical trials. A pioneer in the development of VEGF inhibitors, he has also served for the past decade as assistant clinical professor of ophthalmology at the University of South Carolina School of Medicine.
In a statement, Douglas Love, president and CEO of Annexon, said, “Annexon’s approach to stopping inflammation at the start has shown clinically meaningful functional benefit for patients across neuroinflammatory diseases and now has the potential to change the GA treatment landscape in Europe and the U.S. We are delighted to welcome Lloyd, an established ophthalmology pioneer with decades of experience navigating global clinical landscapes, who will play a key role in the strategic planning, development, and execution of our first-in-kind ophthalmology program. His addition to the Annexon team highlights the growing support of the retina community for a better treatment that preserves vision for dry age-related macular degeneration (AMD) patients with GA and our unique opportunity to address the significant unmet need.”
Dr. Clark commented, “I am thrilled to join the outstanding team at Annexon at this important time for the company as we complete enrollment in our ARCHER II program, putting us on a path towards pivotal Phase 3 data and global registration. ANX007 has shown the potential to preserve vision in patients with dry AMD, which to date has not been seen with any other therapy. I am excited to work with my colleagues, investigators, and the retina community to bring this therapy to patients.”
